Compare ADCT & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADCT | LWLG |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.4M | 578.6M |
| IPO Year | 2019 | 2011 |
| Metric | ADCT | LWLG |
|---|---|---|
| Price | $4.22 | $3.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.60 | N/A |
| AVG Volume (30 Days) | 668.5K | ★ 1.7M |
| Earning Date | 03-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,837,000.00 | $95,605.00 |
| Revenue This Year | $12.48 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.84 | ★ 136.05 |
| 52 Week Low | $1.05 | $0.79 |
| 52 Week High | $4.80 | $6.26 |
| Indicator | ADCT | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 45.83 |
| Support Level | $3.85 | $3.00 |
| Resistance Level | $4.23 | $3.56 |
| Average True Range (ATR) | 0.27 | 0.32 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 95.07 | 59.86 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.